Craft

United Therapeutics

Stock Price

$267.7

2024-05-29

Market Capitalization

$11.9 B

2024-05-29

Revenue

$2.3 B

FY, 2023

United Therapeutics Summary

Company Summary

Overview
United Therapeutics Corporation is a biotechnology company which develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The Company's product candidates include Remodulin, Tyvaso, Orenitram, and Adcirca. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma. In addition, the company develops RemoSynch and RemUnity delivery systems for intravenous and subcutaneous Remodulin, esuberaprost and eNOS gene therapies, and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion.
Type
Public
Status
Active
Founded
1996
HQ
Silver Spring, MD, US | view all locations
Website
http://www.unither.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

LocationsView all

12 locations detected

  • Silver Spring, MD HQ

    United States

    1040 Spring St

  • Blacksburg, VA

    United States

    Blacksburg, VA, USA

  • Durham, NC

    United States

    55 TW Alexander Dr

  • Manchester, NH

    United States

    Manchester, NH, USA

  • Melbourne, FL

    United States

    Melbourne, FL, USA

  • Satellite Beach, FL

    United States

    Satellite Beach, FL, USA

and 6 others

United Therapeutics Financials

Summary Financials

Revenue (Q1, 2024)
$677.7M
Gross profit (Q1, 2024)
$604.8M
Net income (Q1, 2024)
$306.6M
Cash (Q1, 2024)
$1.3B
EBIT (Q1, 2024)
$356.3M
Enterprise value
$11.3B

Footer menu